ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DMA Diamedica Therapeutics

4.63
0.00 (0.00%)
01 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Diamedica Therapeutics TSXV:DMA TSX Venture Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.63 4.57 5.00 0 00:00:00

DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call

18/03/2019 5:56pm

GlobeNewswire Inc.


DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart


From Nov 2019 to Nov 2024

Click Here for more DiaMedica Inc. Charts.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March 19th.  DiaMedica’s management will host a live conference call on Wednesday, March 20th at 8:00am Central Time to provide a business update and discuss the Company’s financial results.

Conference Call details:

Date:March 20, 2019
Time:8:00 AM CT
Web access:https://edge.media-server.com/m6/p/idbwv4bq
Dial In:(866) 962-3593 (domestic)
 (630) 652-5857 (international)
Conference ID:6773627

Listeners should log on to the website or dial in 15 minutes prior to the call.  The webcast will remain available for play back on our website, under investor events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until March 28, 2019, by dialing 1(855) 859-2056 (US Toll Free Dial In), (404) 537-3406 (international), replay passcode 6773627.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visit www.diamedica.com.

Contact:

Scott KellenChief Financial OfficerPhone: (763) 496-5118 skellen@diamedica.com

Paul Papi Vice President of Business Development Phone: (617) 899-5941info@diamedica.com

1 Year DiaMedica Inc. Chart

1 Year DiaMedica Inc. Chart

1 Month DiaMedica Inc. Chart

1 Month DiaMedica Inc. Chart

Your Recent History

Delayed Upgrade Clock